271 related articles for article (PubMed ID: 34316683)
1. CDK12: cellular functions and therapeutic potential of versatile player in cancer.
Pilarova K; Herudek J; Blazek D
NAR Cancer; 2020 Mar; 2(1):zcaa003. PubMed ID: 34316683
[TBL] [Abstract][Full Text] [Related]
2. Gene expression regulation by CDK12: a versatile kinase in cancer with functions beyond CTD phosphorylation.
Choi SH; Kim S; Jones KA
Exp Mol Med; 2020 May; 52(5):762-771. PubMed ID: 32451425
[TBL] [Abstract][Full Text] [Related]
3. Pan-Cancer Analysis of
Sokol ES; Pavlick D; Frampton GM; Ross JS; Miller VA; Ali SM; Lotan TL; Pardoll DM; Chung JH; Antonarakis ES
Oncologist; 2019 Dec; 24(12):1526-1533. PubMed ID: 31292271
[TBL] [Abstract][Full Text] [Related]
4. Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications.
Popova T; Manié E; Boeva V; Battistella A; Goundiam O; Smith NK; Mueller CR; Raynal V; Mariani O; Sastre-Garau X; Stern MH
Cancer Res; 2016 Apr; 76(7):1882-91. PubMed ID: 26787835
[TBL] [Abstract][Full Text] [Related]
5. CDK12 phosphorylates 4E-BP1 to enable mTORC1-dependent translation and mitotic genome stability.
Choi SH; Martinez TF; Kim S; Donaldson C; Shokhirev MN; Saghatelian A; Jones KA
Genes Dev; 2019 Apr; 33(7-8):418-435. PubMed ID: 30819820
[TBL] [Abstract][Full Text] [Related]
6. CDK12 regulates DNA repair genes by suppressing intronic polyadenylation.
Dubbury SJ; Boutz PL; Sharp PA
Nature; 2018 Dec; 564(7734):141-145. PubMed ID: 30487607
[TBL] [Abstract][Full Text] [Related]
7. CDK12 controls G1/S progression by regulating RNAPII processivity at core DNA replication genes.
Chirackal Manavalan AP; Pilarova K; Kluge M; Bartholomeeusen K; Rajecky M; Oppelt J; Khirsariya P; Paruch K; Krejci L; Friedel CC; Blazek D
EMBO Rep; 2019 Sep; 20(9):e47592. PubMed ID: 31347271
[TBL] [Abstract][Full Text] [Related]
8. CDK12: an emerging therapeutic target for cancer.
Lui GYL; Grandori C; Kemp CJ
J Clin Pathol; 2018 Nov; 71(11):957-962. PubMed ID: 30104286
[TBL] [Abstract][Full Text] [Related]
9. Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.
Nguyen B; Mota JM; Nandakumar S; Stopsack KH; Weg E; Rathkopf D; Morris MJ; Scher HI; Kantoff PW; Gopalan A; Zamarin D; Solit DB; Schultz N; Abida W
Eur Urol; 2020 Nov; 78(5):671-679. PubMed ID: 32317181
[TBL] [Abstract][Full Text] [Related]
10. Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy.
Wu W; Yu S; Yu X
Biochim Biophys Acta Rev Cancer; 2023 Jan; 1878(1):188842. PubMed ID: 36460141
[TBL] [Abstract][Full Text] [Related]
11. The promise and current status of CDK12/13 inhibition for the treatment of cancer.
Tadesse S; Duckett DR; Monastyrskyi A
Future Med Chem; 2021 Jan; 13(2):117-141. PubMed ID: 33295810
[TBL] [Abstract][Full Text] [Related]
12. The emerging roles of CDK12 in tumorigenesis.
Paculová H; Kohoutek J
Cell Div; 2017; 12():7. PubMed ID: 29090014
[TBL] [Abstract][Full Text] [Related]
13. CDK12: a potential therapeutic target in cancer.
Emadi F; Teo T; Rahaman MH; Wang S
Drug Discov Today; 2020 Dec; 25(12):2257-2267. PubMed ID: 33038524
[TBL] [Abstract][Full Text] [Related]
14.
Liang S; Hu L; Wu Z; Chen Z; Liu S; Xu X; Qian A
Cells; 2020 Jun; 9(6):. PubMed ID: 32570740
[TBL] [Abstract][Full Text] [Related]
15. CDK12 globally stimulates RNA polymerase II transcription elongation and carboxyl-terminal domain phosphorylation.
Tellier M; Zaborowska J; Caizzi L; Mohammad E; Velychko T; Schwalb B; Ferrer-Vicens I; Blears D; Nojima T; Cramer P; Murphy S
Nucleic Acids Res; 2020 Aug; 48(14):7712-7727. PubMed ID: 32805052
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Wu YM; Cieślik M; Lonigro RJ; Vats P; Reimers MA; Cao X; Ning Y; Wang L; Kunju LP; de Sarkar N; Heath EI; Chou J; Feng FY; Nelson PS; de Bono JS; Zou W; Montgomery B; Alva A; ; Robinson DR; Chinnaiyan AM
Cell; 2018 Jun; 173(7):1770-1782.e14. PubMed ID: 29906450
[TBL] [Abstract][Full Text] [Related]
17. Role and therapeutic potential of CDK12 in human cancers.
Chilà R; Guffanti F; Damia G
Cancer Treat Rev; 2016 Nov; 50():83-88. PubMed ID: 27662623
[TBL] [Abstract][Full Text] [Related]
18. Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types.
Elliott A; Zhang J; Zhang Q; Swensen J; Martin D; Xiu J; Geynisman DM; Vaena D; Herzog TJ; Holloway RW; El-Deiry WS; Spetzler D; Heath E; Stafford P; Korn WM
J Mol Diagn; 2021 Dec; 23(12):1761-1773. PubMed ID: 34562615
[TBL] [Abstract][Full Text] [Related]
19. Cdk12 Is A Gene-Selective RNA Polymerase II Kinase That Regulates a Subset of the Transcriptome, Including Nrf2 Target Genes.
Li X; Chatterjee N; Spirohn K; Boutros M; Bohmann D
Sci Rep; 2016 Feb; 6():21455. PubMed ID: 26911346
[TBL] [Abstract][Full Text] [Related]
20. Th e role of CDK12 in tumor bio logy.
Dzimková M; Procházková J; Klát J; Kohoutek J
Klin Onkol; 2020; 33(4):260-267. PubMed ID: 32894954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
